Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

SKRR Exploration Inc. V.SKRR

Alternate Symbol(s):  SKKRF

SKRR Exploration Inc. is a Canada-based precious metal explorer with properties in Saskatchewan mining jurisdictions. The Company's primary exploration focus is its three gold properties on the Trans-Hudson Corridor in Saskatchewan. The Company’s projects include Nickel Peak Group, Carp River, Manson Bay, Father Lake, Irving, Olson, Ithingo and Cathro. The Carp River property, comprised of five contiguous mineral claims totaling 5,606.48 hectares (ha), is located immediately north of the hamlet of Stony Rapids in the province of Saskatchewan. The 4,293 ha Manson Bay Project is located 40 kilometers (Km) northwest of Flin Flon, Manitoba’s historic mining center and four kilometers southwest of the Schotts Lake Copper-Zinc Deposit in Saskatchewan. The Father Lake property is located 40 km northeast of the hamlet of Stony Rapids in the province of Saskatchewan. The Ithingo Project consists of 12 contiguous mineral claims comprising an overall land package of approximately 2,849 hectares.


TSXV:SKRR - Post by User

Bullboard Posts
Post by DCArnoldon May 27, 2001 3:18pm
262 Views
Post# 3792489

AGM transcript third section

AGM transcript third section Dr. McPherson: We have also moved this program forward into phase III trials in colon cancer and we're currently looking at, I'm sorry phase II, clinical trial program in colorectal cancer and this study was done by Margaret Tempero and reported in ASCO, in May. The data would indicate that, in this setting, there is clear evidence of a dose response relationship at the 1, 10 and 100 ug or unit dose, in terms of antibody response. But what's more important is that if you look at these patients and there were 45 patients with 15 at each of those dose regimens, you can see that these patients, for all 45 patients had a total of 14.2 months for the 45 patients and 12.5 months for the 27 colon cancer patients. Now these are all people with colon cancer who have been treated with first-line chemotherapy, 5-FU, leucovorin, something of that nature and have progressed. Now the median survival for that group of patients is something in the order of 9 to 12 months on chemotherapy so if they have a median survival of 9 to 12 months then they are going to progress at something of the order of a median of 6 months and if you take a look at these people and say 'OK well they've progressed', the 27 progressed at six months, they got another 12.5 months. So they got 18.5, 19 months of survival from the time they first were shown to have metastatic disease in their colon, which is, you know, a very important and quite impressive, small number increase. And this is certainly an area that we will be looking at with our collaborator Merck and EMD. And certainly does suggest that there's possible justification for a randomized trial in this massively difficult disease. And as I've said we're discussing moving this indication into a registration program also with Merck and EMD. Our follow on product is the BLP25, the 25 amino acid sequence that's encapsulated, as shown here, in the yellow globule which is a liposome, is the product that we've taken into non-small cell lung cancer and our phase I trial, which was done with different doses established safety and immunogenicity and, in particular, induced T-cell responses. However, we found that the T-cell responses that we got with that regimen were not as good as we wanted them to be. And remembering that we need to get some pretty good T-cell responses here fairly quickly because these people only have a median survival of 9-10 months with stage IIIb and IV smoker's cancer. So if you've got sort of a three-month period during which they are being treated and then followed, they're well down the road, 33% of the way down the road to death, before you have the first follow up. So, we moved that to a more aggressive program and with this more aggressive program and a higher dose, we found that we got a better T-cell response in six of the first eight patients that we treated. We then added to that liposomal IL-2, in an attempt to see if we could enhance the immune response and that data, to date, indicates that it hasn't, at those doses, increased the immune response. The enrollment's complete and we've looked at the immunogenicity and so we've moved forward with a 166 patient randomized trial in patients who receive BLP25, after chemotherapy, and one group, 83 of them, receives the BLP25, 1000ug subcutaneously, weekly for eight weeks, followed by best standard of care and the second group receives best standard of care after they have received the chemotherapy program. So, both groups have received chemotherapy, shown some indication of usefulness and then are randomly allocated to the two groups, much as the Theratope in the Theratope trial. And we are looking at hopefully completing the enrollment of this trial, unless we move it forward more aggressively and that will be part of our discussion with our collaborator, at the moment it's enrolling rather slowly, we have ten sites in Canada, four in the U.K. The ramp up has been somewhat encouraging in the last month or so but nevertheless if this is going to enroll at an acceptable rate we're going to move more aggressively in this particular area. Patents are the essence, the crown jewels, of bio-pharmaceutical and biotech companies. We have a very solid patent portfolio. One of the things that our collaborators noticed when they did what's called due diligence, prior to signing a collaboration agreement, was to go through our patent portfolio with a fine toothed comb. We've added two, I think, very important patents. One which we've licensed from the Imperial Cancer Research Technology, which is a composition of matter patent, the best kind of patent, and this will be in relationship to our MUC1, BLP25 peptide, which is used in our liposomal cancer vaccine. We've also had another patent issue, which also is a composition of matter patent, and it is a cost effective way of extracting autologous vaccines, patient specific vaccines that can be used in B-cell lymphoma, for instance. And we expect to be moving forward with that, under the protection of that autologous vaccine patent. That trial will begin in 2001 with the National Cancer Institute in the United States under the supervision of Dr. Larry Kwak, a literally world famous hemo-oncologist at the NCI US. Now, it's important to recognize that these one's that I've been talking about are the lead product candidates but if you are going to be investing in a company that's going to have any strength, in terms of staying power, it has to be more than a one trick or a two trick pony. And so Theratope and BLP25 I've talked about but in addition we do have that BLP25/Interleukin-2 program, that product we need to go further with it because we clearly don't have the right dose and the right scheduling for that or maybe the right indication. We have to move forward with the autologous vaccine and we're looking at using this liposomal IL-2 as a single agent, for instance, in renal cell cancer and possibly malignant melanoma. And then beneath that product pipeline, all of which is in clinical settings, we have a fairly strong product portfolio at a pre-clinical level and we're aggressively looking at in-licensing as well as internally developing a product portfolio that will allow us to have staying power and move ahead capability as we go forward. Our financial position, as of now, indicates that as of the end of March we had $49.6 million or $31.2 million US in the bank and we've drawn down on the $100 million equity line financing $67.6 Canadian with still 3.9 million shares available for this equity line financing drawdown. In addition to that, of course, we also have the money, which is in the bank today, in a large measure, from the upfront payments from Merck KGaA. So under those circumstances we feel we are in a reasonable circumstance for having something in excess of two years of cash available to us, with the upfront payments plus the cash and not including the additional drawdown. To finally conclude I want to just leave up for your attention the fact that we have eight particular milestones which we believe we accomplished in 2000 and 2001 and thank you very much for listening to the Biomira story. And, actually, particularly, thank you Pat. End of Presentation. Q and A to follow.
Bullboard Posts